Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Gregory Berk"'
Autor:
Philippa (Pippa) Kennedy, Quinlan Kile, Blake Jacobson, Brianna Ettestad, Nicholas Zorko, Caroline Hallstrom, Behiye Kodal, Deborah Todhunter, Daniel Vallera, Gregory Berk, Jeffrey Miller, Manish Patel, Martin Felices
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41d38afdda294354fde8aa3c1735e5e8
https://doi.org/10.1136/jitc-2022-sitc2022.1202
https://doi.org/10.1136/jitc-2022-sitc2022.1202
Autor:
Antoine N. Saliba, Keith Pietropaolo, Kevin H. Kuo, Ellis J. Neufeld, Vip Viprakasit, Janet L. Kwiatkowski, Alan R. Cohen, Brenda I. Jeglinski, Yesim Aydinok, Patricia J. Giardina, Gregory Berk, Ali T. Taher
Publikováno v:
American journal of hematology. 92(12)
PubMed ID: 28940308
Our phase I, open-label, multi-center, dose-escalation study evaluated the pharmacokinetics (PK) of SP-420, a tridentate oral iron chelating agent of the desferrithiocin class, in patients with transfusion dependent ß-thalas
Our phase I, open-label, multi-center, dose-escalation study evaluated the pharmacokinetics (PK) of SP-420, a tridentate oral iron chelating agent of the desferrithiocin class, in patients with transfusion dependent ß-thalas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5873bc1d1c970d61aae85e5d3d8b48d
https://pubmed.ncbi.nlm.nih.gov/28940308
https://pubmed.ncbi.nlm.nih.gov/28940308
Autor:
Joyce F. Liu, Dejan Juric, Kathy Kerstein, Amita Patnaik, Wael A. Harb, Manish R. Patel, Lei Zheng, Gregory Berk, Suming Wang, Michael Cieslewicz, Jing Watnick, Kathleen N. Moore, Devalingam Mahalingam, Andrea J. Bullock, Robert Guttendorf
Publikováno v:
Journal of Clinical Oncology. 37:TPS3158-TPS3158
TPS3158 Background: VT1021 is a cyclic pentapeptide that functions as a potent inducer of thrombospondin-1 (Tsp-1) expression in the tumor microenvironment (TME). By triggering the production of Tsp-1, VT1021 reprograms the TME from one that is immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc39d06aa17e28a4e9972354a0fccbda
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3158
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3158
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 69:1254-1261
Purpose 5-Iodo-2-pyrimidinone-2′-deoxyribose (IPdR) is a novel orally administered (p.o.) prodrug of 5-iododeoxyuridine. Because p.o. IPdR is being considered for clinical testing as a radiosensitizer in patients with high-grade gliomas, we perform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bedccd1449e1619ad5d44f5a4c6d89
https://doi.org/10.1016/j.ijrobp.2007.08.004
https://doi.org/10.1016/j.ijrobp.2007.08.004
Autor:
Jessica R. Glass, Kalsey Belle, Gregory Berke, Nathalie Bodin, April J. Burt, Murray I. Duncan, Sian K. Morgan, Pavitray Pillay, Sheena Talma
Publikováno v:
Frontiers in Marine Science, Vol 9 (2022)
The Republic of Seychelles is one of six African Small Island Developing States (SIDS) and has a marine-based economy reliant on fisheries and international tourism. Seychelles has been flagged by the United Nations as highly vulnerable to climate ch
Externí odkaz:
https://doaj.org/article/bce0bc18e1a440b5b003dd04d20666aa
Autor:
Jasgit C. Sachdev, Lowell L. Hart, Peter D. Eisenberg, Susan Low, Gregory Berk, Howard A. Burris, Jason Summa, Monica M. Mita, Patricia LoRusso, Alain C. Mita
Publikováno v:
Cancer Research. 74:CT210-CT210
Background: BIND-014 is a novel, targeted, polymeric nanoparticle (NP) containing docetaxel (DTXL). BIND-014 is targeted to prostate-specific membrane antigen (PSMA), a tumor antigen expressed on prostate cancer cells and on the neovasculature of man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe3a2d91ace3998251a4038cdfd54730
https://doi.org/10.1158/1538-7445.am2014-ct210
https://doi.org/10.1158/1538-7445.am2014-ct210
Autor:
Susan Low, Jasgit C. Sachdev, Jeff Hrkach, Howard A. Burris, Ramesh K. Ramanathan, Daniel D. Von Hoff, Glen J. Weiss, Jason Summa, Peter D. Eisenberg, Alain C. Mita, Gregory Berk, Monica M. Mita, Patricia LoRusso, Lowell L. Hart
Publikováno v:
Cancer Research. 74:911-911
Background: Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in prostate adenocarcinomas and in non-prostatic tumor neovasculature. As a novel target for therapeutic approaches, the distribution pattern of PS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cb0c1207ca23c0b6d90812ccc4cc00a
https://doi.org/10.1158/1538-7445.am2014-911
https://doi.org/10.1158/1538-7445.am2014-911
Autor:
Gregory Berk, Glen J. Weiss, Peter D. Eisenberg, Jasgit C. Sachdev, Patricia LoRusso, Ramesh K. Ramanathan, Susan Low, Daniel D. Von Hoff, Alain C. Mita, Monica M. Mita, Jason Summa, Jeff Hrkach
Publikováno v:
Cancer Research. 73:LB-203
Background: BIND-014 is a novel, targeted, polymeric nanoparticle (NP) containing docetaxel (DTXL). BIND-014 is targeted to prostate-specific membrane antigen (PSMA), a tumor antigen expressed on prostate cancer cells and on the neovasculature of man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb8d0901e54a2b3e7412482615147d3d
https://doi.org/10.1158/1538-7445.am2013-lb-203
https://doi.org/10.1158/1538-7445.am2013-lb-203
Autor:
Gregory Berk, Stanley E. Waintraub, Kathleen Grima, L. Helson, Zubair Niazi, C. Puccio, Tanveer Akhtar, M Beer, Karen Seiter, D. E. Lake, Martin Katz, Jeffrey Perchick, Eric J. Feldman, Tauseef Ahmed, Steven Papish, Robert A. Preti, Hoo G. Chun, Abraham Mittelman, Morton Coleman
Publikováno v:
Annals of the New York Academy of Sciences. 770
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9302db2f80dabf24149bf5c18060bfb3
https://pubmed.ncbi.nlm.nih.gov/8597368
https://pubmed.ncbi.nlm.nih.gov/8597368
Autor:
Gregory Berk, Ravi Vij, Peter Lipman, Trinh Le, Jeffrey Matous, Jeffrey L. Wolf, Chirag Patel, Irene M. Ghobrial, Christian Rommel, David S. Siegel, Jesus G. Berdeja
Publikováno v:
Blood. 120:4038-4038
Abstract 4038 Background MLN0128 is an investigational, oral, potent, and selective, ATP site inhibitor of the mTOR complexes 1 and 2 (TORC1/2), and is structurally and mechanistically distinct from rapamycin and rapalogs, which primarily target TORC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d3ab76e42b65cd8c0e9daaf4cc7aef9
https://doi.org/10.1182/blood.v120.21.4038.4038
https://doi.org/10.1182/blood.v120.21.4038.4038